SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer

Chen, Jiyuan; Wu, Zhenjie; Ding, Weihong; Xiao, Chengwu; Zhang, Yu; Gao, Shen; Gao, Yuan; Cai, Weimin

doi:10.7150/thno.40489

Cited by 50 publications

(24 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanoparticles have been reported to increase targeting abilities and efficacies in vivo [7]. Our previous studies demonstrated that small molecules or gene therapy drugs in intelligent nanoplatforms could be accurately delivered to prostate cancer, achieving high efficacy in vitro and in vivo [8][9][10]. Due to the large dose of Enz needed in clinical applications, it is a challenge to intravenously deliver hydrophobic and low permeability drugs such as Enz [11].…”

Section: Introductionmentioning

confidence: 99%

Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Enzalutamide (Enz) has shown limited bioavailability via oral administration. Castration-resistant prostate cancer (CRPC) is frequent among patients receiving 18-24 months of androgen deprivation therapy. The nonsteroidal anti-androgen enzalutamide (Enz) used in the treatment of prostate cancer has shown limited bioavailability via oral administration. Therefore, we developed a multifunctional enzalutamide-loaded graphene oxide nanosystem (TP-GQDss/Enz) for CRPC intravenous treatment, with high drug loading efficiency. Methods: Aminated graphene quantum dots (GQDs) were first cross-linked via disulfide bonds into a graphene quantum dot derivative of approximately 200 nm (GQDss), which was further functionalized with a tumour-targeting peptide and PEG to form TP-GQDss. Enz was loaded into TP-GQDss for in vitro and in vivo study. Results: The results showed that high drug-loading efficiency was achieved by TP-GQDss via π-π electron interaction. TP-GQDss could be rapidly internalized by CRPC cells via endocytosis. Moreover, Enz in TP-GQDss could inhibit the growth of C4-2B and LNCaP prostate cancer cell lines in vitro. Further, TP-GQDss exhibited an enhanced cancertargeting ability and alleviated the side effects of Enz in vivo. Conclusions: The multifunctional nanocarrier constructed here could accomplish controlled Enz release and serve as an intravenous therapy platform for CRPC.

show abstract

Section: Introductionmentioning

confidence: 99%

Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…3 Bone is the most common distant metastatic site in PCa, mainly due to slow blood flow through the bone marrow and abundant adhesion receptors, growth factors and cytokines. [4][5][6] Serious complications accompany bone metastasis, such as pathological fracture, hypercalcemia, nerve compression syndrome and intractable pain. 7 Treatment mainly includes systemic treatment with endocrine therapy and chemotherapy, as well as local treatment for bone metastasis, such as surgery, radiotherapy, and bisphosphonates, which usually lead to drug resistance and harmful side effects.…”

Section: Introductionmentioning

confidence: 99%

“…4,5 The scope of gene therapy has been extended from genes to various nucleic acids such as antisense oligonucleotides (ASOs), siRNA, miRNA and mRNA. [6][7][8][9][10] Many lines of evidence have demonstrated that miRNA-based therapies hold great prospects in the treatment of PCa. 7,11 In our previous study, miRNA-133a-3p was proven to be a tumor suppressor gene in prostate cancer and downregulates several cytokine receptors associated with PCa growth, including FGFR, EGFR, IGFR and MET, inactivating the PI3K/AKT signaling pathway.…”

Section: Introductionmentioning

confidence: 99%

<p>PSMA-Targeting Reduction-Cleavable Hyperbranched Polyamide-Amine Gene Delivery System to Treat the Bone Metastases of Prostate Cancer</p>

Zhang

Dai

et al. 2020

IJN

View full text Add to dashboard Cite

This study aimed to develop aptamer-anchored hyperbranched poly(amido amine) (HPAA) for the systemic delivery of miRNA-133a-3p and to evaluate its therapeutic potential against bone metastasis of prostate cancer in vivo and in vitro. Methods: A glutathione (GSH)-responsive cationic HPAA was prepared by the Michael addition reaction. Furthermore, HPAA-PEG was produced by PEGylation, and then the aptamer targeted to prostate-specific membrane antigen (PSMA) was conjugated to the HPAA-PEG. The obtained HPAA-PEG-APT could form nanocomplexes with miRNA-133a-3p through electrostatic adsorption. Results: The results of immunocytochemistry indicated that the complexes could target PSMA-expressing LNCaP cells. The ability of HPAA-PEG-APT to facilitate the delivery of miRNA-133a-3p into LNCaP cells was proven, and HPAA-PEG-APT/miRNA-133a-3p demonstrated enhanced antitumor activity, lower cytotoxicity and better biocompatibility in vitro. Moreover, in a mouse tibial injection tumor model, the intravenous injection of the HPAA-PEG-APT/miRNA-133a-3p complex significantly inhibited cancer growth and extended the survival time. Conclusion: This study provided an aptamer-anchored HPAA-loaded gene system to deliver miRNA-133a-3p for better therapeutic efficacy of bone metastasis of prostate cancer.

show abstract

“…However, advanced prostate cancer frequently metastasizes after chemotherapy, surgery and radiotherapy 3 . Bone is the most common distant metastatic site in PCa, mainly due to slow blood ow through the bone marrow and abundant adhesion receptors, growth factors and cytokines [4][5][6] . Serious complications accompany bone metastasis, such as pathological fracture, hypercalcemia, nerve compression syndrome and intractable pain 7 .…”

Section: Introductionmentioning

confidence: 99%

“…The emergence of gene therapy has brought a new direction for the treatment of cancer [4,5] . The scope of gene therapy has been extended from genes to various nucleic acids such as antisense oligonucleotides (ASOs), siRNA, miRNA and mRNA [6][7][8][9][10] . Many lines of evidence have demonstrated that miRNA-based therapies hold great prospects in the treatment of PCa [7,11] .…”

Section: Introductionmentioning

confidence: 99%

PSMA-Targeting Redox Hyperbranched Poly (Amido Amine)-Mediated miR-133a-3p Delivery to Inhibit Bone Metastasis of Prostate Cancer

Ye¹,

Zhang²,

Dai³

et al. 2020

Preprint

View full text Add to dashboard Cite

Treatment of bone metastasis of prostate cancer remains a formidable challenge. The skeleton has a poorer blood supply, leading to inadequate drug distribution into the bone after administration. This study aimed to develop aptamer-anchored hyperbranched poly (amido amine) (HPAA) for the systemic delivery of miRNA-133a-3p and to evaluate its therapeutic potential against bone metastasis of prostate cancer in vivo and in vitro. A glutathione (GSH)-responsive cationic HPAA was prepared by the Michael addition reaction. Furthermore, HPAA-PEG was produced by PEGylation, and then the aptamer targeted to prostate-specific membrane antigen (PSMA) was conjugated to the HPAA-PEG. The obtained HPAA-PEG-APT could form nanocomplexes with miRNA-133a-3p through electrostatic adsorption. The results of immunocytochemistry indicated that the complexes could target PSMA-expressing LNCaP cells. The ability of HPAA-PEG-APT to facilitate the delivery of miRNA-133a-3p into LNCaP cells was proven, and HPAA-PEG-APT/miRNA-133a-3p demonstrated enhanced antitumor activity, lower cytotoxicity and better biocompatibility in vitro. Moreover, in a mouse tibial injection tumor model, the intravenous injection of the HPAA-PEG-APT/miRNA-133a-3p complex significantly inhibited cancer growth and extended the survival time. In summary, this study provided an aptamer-anchored HPAA-loaded gene system to deliver miRNA-133a-3p for better therapeutic efficacy of bone metastasis of prostate cancer.

show abstract

SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer

Cited by 50 publications

References 46 publications

Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

<p>PSMA-Targeting Reduction-Cleavable Hyperbranched Polyamide-Amine Gene Delivery System to Treat the Bone Metastases of Prostate Cancer</p>

PSMA-Targeting Redox Hyperbranched Poly (Amido Amine)-Mediated miR-133a-3p Delivery to Inhibit Bone Metastasis of Prostate Cancer

Contact Info

Product

Resources

About